Résultats des patients cancéreux atteints par la Covid-19 (notice n° 271382)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03050cam a2200325 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112080541.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Boţ, Alexandra-Cristina |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Résultats des patients cancéreux atteints par la Covid-19 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2020.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 66 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméLa gravité de l’association entre Covid-19 et cancer reste un sujet controversé. Entre avril et juin 2020, à l’Institut de cancérologie de Cluj, Roumanie, 44 patients ont présenté un test RT-PCR (transcriptase inverse-réaction en chaîne par polymérase) positif. Au cours de l’infection, 31,8 % sont restés asymptomatiques, 15,9 % ont développé une forme légère, 31,8 % une forme moyenne et 11,4 % une forme grave de Covid-19 avec décès. Le sexe masculin et le cancer avancé actif ont représenté les seuls facteurs pronostiques négatifs en analyse univariée. Le traitement a inclus l’hydroxychloroquine (57,5 % des patients), les anticoagulants (52,5 %), le paracétamol (47,5 %), le lopinavir/ritonavir (45 %) et l’azithromycine (42,5 %). Dans notre série, l’incidence de l’infection par le SARS-CoV-2 a été similaire chez les patients cancéreux et la population générale. La différence du taux de mortalité n’a pas été statistiquement significative (11,4 % versus 4,9 %, p = 0,11). |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The seriousness of the association between Covid-19 and cancer remains a controversial topic. Between April and June 2020 at the Institute of Oncology in Cluj, 44 patients presented with a positive RT-PCR test. During the infection, 31.8% remained asymptomatic, 15.9 developed a mild form, 31.8% had a moderate form, and 11.4% a severe form of Covid-19 that led to death. Male sex and advanced active cancer were the only negative prognostic factors based on the univariate analysis. Treatment included hydroxychloroquine (23/40; 57.5%), anticoagulants (21/40; 52.5%), paracetamol (19/40; 47.5%), lopinavir/ritonavir (18/40; 45%), and azithromycin (17/40; 42.5%). In our series, the incidence of Covid-19 infection was similar between cancer patients and the general population and the difference in death rate was also not statistically significant (11.4% vs 4.9%; p = 0.11). With active testing, we are attempting to keep the institute coronavirus-free. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pandémie Covid-19 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pronostic |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | prognostic |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Covid-19 outbreak |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Todor, Nicolae |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bălăcescu, Ovidiu |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cadariu, Patriciu-Achimaş |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vlad, Cătălin |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lupşe, Mihaela |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Briciu, Violeta Tincuţa |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ciuleanu, Tudor-Eliade |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 6 | 3 | 2020-05-01 | p. 155-160 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2020-3-page-155?lang=fr">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2020-3-page-155?lang=fr</a> |
Pas d'exemplaire disponible.
Réseaux sociaux